{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/138869840"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "As evidenced by our robust pipeline, our antisense drug discovery technology is applicable to many different diseases.??? This indicates that Isis considers the approval of mipomersen as a proof-of-concept for its approach to antisense oligonucleotide drug discovery and development, and in particular for its pipeline." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "biopharmconsortium.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/83753682"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/138869840"] } } }
